Stay updated on Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.

Latest updates to the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe page displays a new revision tag: Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a metadata/version update rather than a substantive change to study content.SummaryDifference0.0%

- Check39 days agoChange DetectedMinor version update from v3.4.0 to v3.4.1; no substantive changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedUI and metadata updates were applied: show/hide glossary options, capitalization adjustments (Last Update Submitted that Met QC Criteria, No FEAR Act data), and a new revision tag (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 and the previous label removed. This appears to be a minor site update that does not affect the study details or eligibility criteria.SummaryDifference0.0%

- Check89 days agoChange DetectedAdded a dedicated Locations section with state-level entries (California, Illinois, Iowa, Maine, Minnesota, New Hampshire, New York, Ohio, Oklahoma) and reorganized the location listings. Page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.8%

Stay in the know with updates to Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.